The firm shows a Beta (market volatility) of 0.0, which signifies not very significant fluctuations relative to the market. the returns on MARKET and Bionik Laboratories are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak
Strong
Over the last 90 days Bionik Laboratories Corp has generated negative risk-adjusted returns adding no value to investors with long positions. Despite quite persistent forward-looking signals, Bionik Laboratories is not utilizing all of its potentials. The newest stock price mess, may contribute to short-term losses for the institutional investors. ...more
Begin Period Cash Flow
608.3 K
Total Cashflows From Investing Activities
-12.5 K
Bionik
Bionik Laboratories Relative Risk vs. Return Landscape
If you would invest 0.01 in Bionik Laboratories Corp on October 31, 2025 and sell it today you would earn a total of 0.00 from holding Bionik Laboratories Corp or generate 0.0% return on investment over 90 days. Bionik Laboratories Corp is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than Bionik, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
Expected Return
Risk
Bionik Laboratories Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Bionik Laboratories for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Bionik Laboratories Corp can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Bionik Laboratories generated a negative expected return over the last 90 days
Bionik Laboratories has some characteristics of a very speculative penny stock
Bionik Laboratories has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 1.27 M. Net Loss for the year was (10.41 M) with profit before overhead, payroll, taxes, and interest of 953.26 K.
Bionik Laboratories Corp currently holds about 1.33 M in cash with (4.15 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.19, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Roughly 62.0% of the company shares are held by company insiders
Bionik Laboratories Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Bionik Pink Sheet often depends not only on the future outlook of the current and potential Bionik Laboratories' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Bionik Laboratories' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding
5.8 M
Cash And Short Term Investments
2 M
Bionik Laboratories Fundamentals Growth
Bionik Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Bionik Laboratories, and Bionik Laboratories fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Bionik Pink Sheet performance.
By examining Bionik Laboratories' fundamental ratios, stakeholders can obtain critical insights into Bionik Laboratories' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Bionik Laboratories is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Bionik Laboratories Corp., a robotics company, engages in designing, developing, and commercializing physical rehabilitation technologies, prosthetics, and assisted robotic products. Bionik Laboratories Corp. was incorporated in 2010 and is headquartered in Watertown, Massachusetts. BIONIK LABORATORIES operates under Medical Care Facilities classification in the United States and is traded on OTC Exchange. It employs 12 people.
Things to note about Bionik Laboratories Corp performance evaluation
Checking the ongoing alerts about Bionik Laboratories for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Bionik Laboratories Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Bionik Laboratories generated a negative expected return over the last 90 days
Bionik Laboratories has some characteristics of a very speculative penny stock
Bionik Laboratories has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 1.27 M. Net Loss for the year was (10.41 M) with profit before overhead, payroll, taxes, and interest of 953.26 K.
Bionik Laboratories Corp currently holds about 1.33 M in cash with (4.15 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.19, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Roughly 62.0% of the company shares are held by company insiders
Evaluating Bionik Laboratories' performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Bionik Laboratories' pink sheet performance include:
Analyzing Bionik Laboratories' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Bionik Laboratories' stock is overvalued or undervalued compared to its peers.
Examining Bionik Laboratories' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
Evaluating Bionik Laboratories' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Bionik Laboratories' management team can help you assess the Company's leadership.
Pay attention to analyst opinions and ratings of Bionik Laboratories' pink sheet. These opinions can provide insight into Bionik Laboratories' potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Bionik Laboratories' pink sheet performance is not an exact science, and many factors can impact Bionik Laboratories' pink sheet market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.
Other Information on Investing in Bionik Pink Sheet
Bionik Laboratories financial ratios help investors to determine whether Bionik Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Bionik with respect to the benefits of owning Bionik Laboratories security.